Home Featured Page 134

Featured

Latest

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Optimi Health Submits Phase I Clinical Trial Application Combining The Use...

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New...

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal...

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma...

Psychedelics Weekly – Research Explained: Ketamine and the Corticothalamic Network, Psilocybin...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Australia Recognises MDMA and Psilocybin as Medicines

A Spotlight on Psychedelic Research Methods

Panel: Psychedelic Research Methods

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

Optimi Health Submits Phase I Clinical Trial Application Combining The Use...

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New...

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal...

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma...

Psychedelics Weekly – Research Explained: Ketamine and the Corticothalamic Network, Psilocybin...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Australia Recognises MDMA and Psilocybin as Medicines

A Spotlight on Psychedelic Research Methods

Panel: Psychedelic Research Methods

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY